Alexion Pharmaceuticals, Inc.’s Acquisition of Wilson Therapeutics


BofA Merrill Lynch is acting as Alexion’s lead financial advisor. Deutsche Bank is also serving as a financial advisor, and DNB Markets is acting as Nordic financial advisor and Settlement Agent. Advokatfirman Cederquist is acting as Alexion’s legal advisor as to Swedish law, and Ropes & Gray LLP is acting as legal advisor as to U.S. law in connection with the Offer. Lazard is acting as exclusive financial adviser to Wilson Therapeutics, and Vinge is serving as legal counsel to Wilson Therapeutics.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has made a recommended public cash offer to the shareholders in Wilson Therapeutics to acquire all outstanding shares in Wilson Therapeutics by way of a tender offer, through a wholly-owned subsidiary.

Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare copper-mediated disorders. Wilson Therapeutics’ product, WTX101, is in Phase 3 development as a treatment for Wilson disease, a rare genetic disorder with devastating hepatic and neurological consequences for patients. WTX101 is a first-in-class oral copper-binding agent with a unique mechanism of action and ability to access and bind copper from serum and promote its removal from the liver. WTX101 has received Fast Track designation in the U.S. and Orphan Drug Designation for the treatment of Wilson disease in the U.S. and EU.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, researches and develops proprietary immunoregulatory compounds for the treatment of autoimmune and cardiovascular diseases.Alexion Pharmaceuticals, Inc., a biopharmaceutical company, researches and develops proprietary immunoregulatory compounds for the treatment of autoimmune and cardiovascular diseases. The company, led by Ludwig N Hantson, Paul J Clancy and Brian Goff, in 2017 recorded $3.551 Billion Revenues.

Ropes & Gray acted as U.S. legal advisor to Alexion Pharmaceuticals, Inc. with a team including Zachary Blume (Picture), antitrust counsel Deidre Johnson, Stephen Hall, Michael Sweeney and Derek Yee.

Cederquist advised with a team including Wilhelm Lüning, Fredrik Lundén, Elin Ljungström, Sara Hag and Björn Sjöberg (Corporate / Capital Markets).

Vinge advised Wilson Therapeutics with a team including Erik Sjöman, Christian Lindhé, Astrid Karlsson and Philip Åberg.

Involved fees earner: Zachary Blume – Ropes & Gray; Stephen Hall – Ropes & Gray; Michael Sweeney – Ropes & Gray; Deidre Johnson – Ropes & Gray; Derek Yee – Ropes & Gray; Wilhelm Lüning – Cederquist KB; Fredrik Lundén – Cederquist KB; Elin Ljungström – Cederquist KB; Sara Hag – Cederquist KB; Björn Sjöberg – Cederquist KB; Erik Sjöman – Vinge; Christian Lindhé – Vinge; Astrid Karlsson – Vinge; Philip Åberg – Vinge;

Law Firms: Ropes & Gray; Cederquist KB; Vinge;

Clients: Alexion Pharmaceuticals; Wilson Therapeutics AB;

Print Friendly, PDF & Email
Avatar

Author: Ambrogio Visconti